MediLink Therapeutics (Suzhou) Co., Ltd.

https://www.medilinkthera.com

MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary Tumor Microenviroment Activable LINker-payload (TMALIN®) ADC technology platform. It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. We focus clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients. Our headquarter is located in Suzhou and has established R&D subsidiaries in Shanghai and Boston. *

	Start	2020-01-01 established
	Group	MediLink Therapeutics (Group)
	Industry	antibody-drug conjugate (ADC)
	Industry 2	TMALIN® ADC platform technology (Tumor Microenvironment Activable LINker-payload )

	Region	Suzhou
	Country	China
	City	n. a. Suzhou
		Address record changed: 2023-10-15

Basic data	Employees	n. a.

		* Document for »About Section«: MediLink Therapeutics (Suzhou) Co., Ltd.. (10/12/23). "Press Release: MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate". Suzhou.

		Record changed: 2025-03-16